Search Results - "Vaslin Chessex, Anne"

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations by Voss, Martin H, Hierro, Cinta, Heist, Rebecca S, Cleary, James M, Meric-Bernstam, Funda, Tabernero, Josep, Janku, Filip, Gandhi, Leena, Iafrate, A John, Borger, Darrell R, Ishii, Nobuya, Hu, Youyou, Kirpicheva, Yulia, Nicolas-Metral, Valerie, Pokorska-Bocci, Anna, Vaslin Chessex, Anne, Zanna, Claudio, Flaherty, Keith T, Baselga, Jose

“…To investigate tolerability, efficacy, and pharmacokinetics/pharmacodynamics of Debio 1347, a selective FGFR inhibitor. This was a first-in-human, multicenter,…”
Get full text

FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma by Cleary, James M, Raghavan, Srivatsan, Wu, Qibiao, Li, Yvonne Y, Spurr, Liam F, Gupta, Hersh V, Rubinson, Douglas A, Fetter, Isobel J, Hornick, Jason L, Nowak, Jonathan A, Siravegna, Giulia, Goyal, Lipika, Shi, Lei, Brais, Lauren K, Loftus, Maureen, Shinagare, Atul B, Abrams, Thomas A, Clancy, Thomas E, Wang, Jiping, Patel, Anuj K, Brichory, Franck, Vaslin Chessex, Anne, Sullivan, Ryan J, Keller, Rachel B, Denning, Sarah, Hill, Emma R, Shapiro, Geoffrey I, Pokorska-Bocci, Anna, Zanna, Claudio, Ng, Kimmie, Schrag, Deborah, Jänne, Pasi A, Hahn, William C, Cherniack, Andrew D, Corcoran, Ryan B, Meyerson, Matthew, Daina, Antoine, Zoete, Vincent, Bardeesy, Nabeel, Wolpin, Brian M

“…We conducted next-generation DNA sequencing on 335 biliary tract cancers and characterized the genomic landscape by anatomic site within the biliary tree. In…”
Get more information

Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases by Murone, Maximilien, Vaslin Chessex, Anne, Attinger, Antoine, Ramachandra, Raghuveer, Shetty, Shankar J, Daginakatte, Girish, Sengupta, Saumitra, Marappan, Sivapriya, Dhodheri, Samiulla, Rigotti, Stefania, Bachhav, Yogeshwar, Brienza, Silvano, Traxler, Peter, Lang, Marc, Aguet, Michel, Zoete, Vincent, Michielin, Olivier, Nicholas, Courtney, Johnson, Faye M, Ramachandra, Murali, McAllister, Andres

“…Tumor survival, metastases, chemoresistance, and escape from immune responses have been associated with inappropriate activation of STAT3 and/or STAT5 in…”
Get full text

Towards a translational computational model of allergen challenge in mild asthma to support clinical development of an intranasal administration of a bacterial lysate by Arsène, Simon, Faddeenkov, Igor, Galland, Théo, Leon, Cristhyne, Lehr, Lorenz, Sansone, Caterina, Vaslin-Chessex, Anne, Pasquali, Christian, Kulesza, Alexander

Get full text

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers by Zingg, Daniel, Bhin, Jinhyuk, Yemelyanenko, Julia, Kas, Sjors M., Rolfs, Frank, Lutz, Catrin, Lee, Jessica K., Klarenbeek, Sjoerd, Silverman, Ian M., Annunziato, Stefano, Chan, Chang S., Piersma, Sander R., Eijkman, Timo, Badoux, Madelon, Gogola, Ewa, Siteur, Bjørn, Sprengers, Justin, de Klein, Bim, de Goeij-de Haas, Richard R., Riedlinger, Gregory M., Ke, Hua, Madison, Russell, Drenth, Anne Paulien, van der Burg, Eline, Schut, Eva, Henneman, Linda, van Miltenburg, Martine H., Proost, Natalie, Zhen, Huiling, Wientjens, Ellen, de Bruijn, Roebi, de Ruiter, Julian R., Boon, Ute, de Korte-Grimmerink, Renske, van Gerwen, Bastiaan, Féliz, Luis, Abou-Alfa, Ghassan K., Ross, Jeffrey S., van de Ven, Marieke, Rottenberg, Sven, Cuppen, Edwin, Chessex, Anne Vaslin, Ali, Siraj M., Burn, Timothy C., Jimenez, Connie R., Ganesan, Shridar, Wessels, Lodewyk F. A., Jonkers, Jos

“…Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast growth factor receptor 2 (encoded by FGFR2 ) occur in multiple types…”
Get full text

Abstract 4703: The inhibitor of apoptosis protein (IAP) antagonist Debio 1143 enhances the immune response to anti-PD1/L1 inhibitors in vitro and in vivo by Attinger, Antoine, Gavillet, Bruno, Chessex, Anne Vaslin, Wiedemann, Norbert, Vuagniaux, Gregoire

“…Abstract Background: Debio 1143 is an oral antagonist of IAPs, currently in clinical development, which sensitizes tumor cells to radiation- or…”
Get full text

Abstract 2303: The WEE1 inhibitor Debio 0123 enhances the efficacy of standard of care DNA damaging agents in lung cancer models by Piggott, Luke, Vaslin-Chessex, Anne, Luong, Noemie, Tschumi, Benjamin, Vuagniaux, Gregoire

“…Abstract Introduction: The WEE1 tyrosine kinase is activated upon DNA damage and regulates the G2-M and S phase cell cycle checkpoints. Inhibition of WEE1, in…”
Get full text

Abstract 4423: Antitumor activity of the novel oral highly selective Wee1 inhibitor Debio 0123 by O'Dowd, Colin, Gavory, Gerald, Burkamp, Frank, Treder, Adam, Boyd, Caroline, Harrison, Tim, Massière, Frederic, Glück, Astrid, Chardonnens, Christophe, Zaffalon, Andrea, Rigotti, Stefania, Mader, Robert, Vuagniaux, Grégoire, Chessex, Anne Vaslin

“…Abstract Background: The Wee1 tyrosine kinase is activated upon DNA damage and regulates the G2-M cell cycle checkpoint. Inhibition of Wee1, in conjunction…”
Get full text

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers by Zingg, Daniel, Bhin, Jinhyuk, Yemelyanenko, Julia, Kas, Sjors M., Rolfs, Frank, Lutz, Catrin, Lee, Jessica K., Klarenbeek, Sjoerd, Silverman, Ian M., Annunziato, Stefano, Chan, Chang S., Piersma, Sander R., Eijkman, Timo, Badoux, Madelon, Gogola, Ewa, Siteur, Bjørn, Sprengers, Justin, de Klein, Bim, de Goeij-de Haas, Richard R., Riedlinger, Gregory M., Ke, Hua, Madison, Russell, Drenth, Anne Paulien, van der Burg, Eline, Schut, Eva, Henneman, Linda, van Miltenburg, Martine H., Proost, Natalie, Zhen, Huiling, Wientjens, Ellen, de Bruijn, Roebi, de Ruiter, Julian R., Boon, Ute, de Korte-Grimmerink, Renske, van Gerwen, Bastiaan, Féliz, Luis, Abou-Alfa, Ghassan K., Ross, Jeffrey S., van de Ven, Marieke, Rottenberg, Sven, Cuppen, Edwin, Chessex, Anne Vaslin, Ali, Siraj M., Burn, Timothy C., Jimenez, Connie R., Ganesan, Shridar, Wessels, Lodewyk F. A., Jonkers, Jos

Get full text

The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34 + Stem/Progenitor Cells by Murone, Maximilien, Radpour, Ramin, Attinger, Antoine, Chessex, Anne Vaslin, Huguenin, Anne-Laure, Schürch, Christian M, Banz, Yara, Sengupta, Saumitra, Aguet, Michel, Rigotti, Stefania, Bachhav, Yogeshwar, Massière, Frédéric, Ramachandra, Murali, McAllister, Andres, Riether, Carsten

“…Acute myelogenous leukemia (AML) is initiated and maintained by leukemia stem cells (LSC). LSCs are therapy-resistant, cause relapse, and represent a major…”
Get full text